Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.59 |
| ▸ | TK1 | P04183 | 1/20 | 0.55 |
| ▸ | TK2 | O00142 | 2/20 | 0.55 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1903632 | 0.90 | TYMP (0.55) | TYMPTK1TK2DNPH1 | |
| SCHEMBL7743877 | 0.90 | TYMP (0.57) | TYMPTK1TK2 | |
| SCHEMBL16620094 | 0.88 | TYMP (0.58) | TYMPTK1TK2 | |
| SCHEMBL15329291 | 0.88 | TYMP (0.58) | TYMPTK1TK2 | |
| SCHEMBL31685257 | 0.88 | DNPH1 (0.55) | TK2DNPH1 | |
| SCHEMBL31685507 | 0.87 | P2RY6 (0.61) | DNPH1 | |
| SCHEMBL31685253 | 0.87 | DNPH1 (0.72) | TK2DNPH1 | |
| SCHEMBL24263988 | 0.86 | TK2 (0.58) | TYMPTK2 | |
| SCHEMBL15691496 | 0.86 | TK2 (0.58) | TYMPTK2 | |
| SCHEMBL19132641 | 0.86 | TK2 (0.58) | TYMPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | TEAM MEDICAL, LLC | 2025-09-18 | — | — | US | claimed |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-08-07 | — | — | US | claimed |
| EP-4594484-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-08-06 | — | — | EP | claimed |
| EP-4568682-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| EP-4569114-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | Sirius Therapeutics, Inc. (US) | 2025-06-18 | — | — | EP | claimed |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | SIRIUS THERAPEUTICS, INC. | 2025-06-12 | — | — | US | claimed |
| CN-120076811-A | Polynucleic acid molecules, pharmaceutical compositions and uses thereof for inhibiting the expression of Lp (a) | 靖因药业有限公司 | 2025-05-30 | — | — | CN | claimed |
| WO-2024073363-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2024-04-04 | — | — | WO | claimed |
| WO-2024035898-A2 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | claimed |
| WO-2024035899-A2 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2024-02-15 | — | — | WO | claimed |
| WO-2025264546-A1 | LIPID-POLYNUCLEIC ACID CONJUGATE COMPOSITIONS AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025264548-A2 | MODIFIED POLYNUCLEIC ACID MOLECULES TARGETING AGT AND USES THEREOF | SIRIUS THERAPEUTICS, INC. (US) | 2025-12-26 | — | — | WO | disclosed |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | ALNYLAM PHARMACEUTICALS INC (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250361508-A1 | POLYNUCLEIC ACID MOLECULES TARGETING AGT AND USES THEREOF | SIRIUS THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-8168775-B2 | Compositions and methods for inhibiting expression of transthyretin | ALNYLAM PHARMACEUTICALS, INC. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110263684-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | disclosed |
| US-20110118340-A1 | DELIVERY OF RNAI CONSTRUCTS TO OLIGODENDROCYTES | ALNYLAM PHARMACEUTICALS, INC. | 2011-05-19 | — | — | US | disclosed |
| US-20100222417-A1 | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues | ALNYLAM PHARMACEUTICALS (US) | 2010-09-02 | — | — | US | disclosed |
| US-20100120893-A1 | Compositions and Methods for Inhibiting Expression of Transthyretin | BANK OF AMERICA, N.A. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118340-A1 | DELIVERY OF RNAI CONSTRUCTS TO OLIGODENDROCYTES | AS3MT, NSUN2, FBL | TYMP 1173/4885TK1 1969/4885TK2 1530/4885 |
| US-20100222417-A1 | Compostions and methods for enhancing oligonucleotide delivery across and into epithelial tissues | RNASE1, MTREX, FABP2 | TYMP 1469/4885TK1 533/4885TK2 1077/4885 |
| US-20250188464-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF LP(A), PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | LPL, LDLR, PNLIP | TYMP 538/4885TK1 497/4885TK2 686/4885 |
| US-20100120893-A1 | Compositions and Methods for Inhibiting Expression of Transthyretin | TTR, RNGTT, RNASE1 | TYMP 58/4885TK1 284/4885TK2 619/4885 |
| US-20250361508-A1 | POLYNUCLEIC ACID MOLECULES TARGETING AGT AND USES THEREOF | AGT, AGTR1, AGTR2 | TYMP 92/4885TK1 65/4885TK2 90/4885 |
| US-20250376682-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF TRANSTHYRETIN | TTR, RNGTT, RNASE1 | TYMP 58/4885TK1 284/4885TK2 619/4885 |
| US-20110263684-A1 | Lipid Formulated Compositions and Methods for Inhibiting Expression of Serum Amyloid A Gene | SAAL1, APOB, SCARB1 | TYMP 3302/4885TK1 3993/4885TK2 4435/4885 |
| US-20250289840-A1 | RNA STABILIZING SUBSTANCES AND METHODS OF USE | SYNCRIP, SNRPA, RNASE1 | TYMP 1847/4885TK1 950/4885TK2 2050/4885 |
| US-20250250573-A1 | POLYNUCLEIC ACID MOLECULES FOR INHIBITING EXPRESSION OF FXI, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | F13B, F13A1, F12 | TYMP 450/4885TK1 1102/4885TK2 1229/4885 |
| US-20250188465-A1 | POLYNUCLEIC ACID MOLECULES TARGETING APOC3 AND USES THEREOF | APOB, APOL1, NOP10 | TYMP 1310/4885TK1 1749/4885TK2 1334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.